Acute Kidney Injury
contrast-induced nephropathy, Am J Cardiol, 2006;98(6A):27K–36K.
12. McCullough PA, Wolyn R, Rocher LL, et al., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality, Am J Med, 1997;103(5):368–75.
13. Brown JR, Robb JF, Block CA, et al., Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?, Circ Cardiovasc Interv, 2010;3(4):346–50.
14. Saklayen MG, Gupta S, Suryaprasad A, Azmeh W, Incidence of atheroembolic renal failure after coronary angiography. A prospective study, Angiology, 1997;48(7):609–13.
15. Scolari F, Ravani P, Pola A, et al., Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study, J Am Soc Nephrol, 2003;14(6):1584–90.
16. Theriault J, Agharazzi M, Dumont M, et al., Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases, Nephron Clin Pract, 2003;94(1):c11–8.
17. Barrett BJ, Parfrey PS, Clinical practice. Preventing nephropathy induced by contrast medium, N Engl J Med, 2006;354(4):379–86.
18. Mehran R, Nikolsky E, Contrast-induced nephropathy: definition, epidemiology, and patients at risk, Kidney Int Suppl, 2006(100):S11–5.
19. Brown JR, DeVries JT, Piper WD, et al., Serious renal dysfunction after percutaneous coronary interventions can be predicted, Am Heart J, 2008;155(2):260–6.
20. Bartholomew BA, Harjai KJ, Dukkipati S, et al., Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification, Am J Cardiol, 2004;93(12):1515–9.
21. Mehran R, Aymong ED, Nikolsky E, et al., A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation, J Am Coll Cardiol, 2004;44(7):1393–9.
22. McCoy AB, Waitman LR, Gadd CS, et al., A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report, Am J Kidney Dis, 2010;56(5):832–41.
23. Matheny ME, Miller RA, Ikizler TA, et al., Development of inpatient risk stratification models of acute kidney injury for use in electronic health records, Med Decis Making, 2010;30(6):639–50.
24. Shahian DM, Torchiana DF, Shemin RJ, et al., Massachusetts cardiac surgery report card: implications of statistical methodology, Ann Thorac Surg, 2005;80(6):2106–13.
25. Glance LG, Dick A, Osler TM, et al., Impact of changing the statistical methodology on hospital and surgeon ranking: the case of the New York State cardiac surgery report card, Med Care, 2006;44(4):311–9.
26. Matheny ME, Ohno-Machado L, Resnic FS, Monitoring device safety in interventional cardiology, J Am Med Inform Assoc, 2006;13(2):180–7.
27. Resnic FS, Gross TP, Marinac-Dabic D, et al., Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices, JAMA, 2010;304(18):2019–27.
28. Barringhaus KG, Zelevinsky K, Lovett A, et al., Impact of independent data adjudication on hospital-specific estimates of risk-adjusted mortality following percutaneous coronary interventions in massachusett, Circ Cardiovasc Qual Outcomes, 2011;4(1):92–8.
29. Ettinger WH, Hylka SM, Phillips RA, et al., When things go wrong: the impact of being a statistical outlier in publicly reported coronary artery bypass graft surgery mortality data, Am J Med Qual, 2008;23(2):90–5.
30. Bouzas-Mosquera A, Vazquez-Rodriguez JM, Calvino-Santos R, et al., Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors and prognosis, Rev Esp Cardiol, 2007;60(10):1026–34.
31. Soofi MA, Frequency of Acute Renal Failure after Cardiac Catheterization and Percutaneous Intervention, Pak J Med Sci, 2006;22(4):446–50.
32. Hennessy SA, LaPar DJ, Stukenborg GJ, et al., Cardiac catheterization within 24 hours of valve surgery is significantly associated with acute renal failure, J Thorac Cardiovasc Surg, 2010;140(5):1011–7.
33. Gupta R, Gurm HS, Bhatt DL, et al., Renal failure after percutaneous coronary intervention is associated with high mortality, Catheter Cardiovasc Interv, 2005;64(4):442–8.
34. Morcos SK, Thomsen HS, European Society of Urogenital R. European Society of Urogenital Radiology guidelines on administering contrast media, Abdom Imaging, 2003;28(2):187–90.
35. Bellomo R, Ronco C, Kellum JA, et al., Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus
Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, 2004;8(4):R204–12.
36. Mehta RL, Kellum JA, Shah SV, et al., Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury, Crit Care, 2007;11(2):R31.
37. Gruberg L, Mehran R, Dangas G, et al., Acute renal failure requiring dialysis after percutaneous coronary interventions, Catheter Cardiovasc Interv, 2001;52(4):409–16.
38. Iakovou I, Dangas G, Mehran R, et al., Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention, J Invasive Cardiol, 2003;15(1):18–22.
39. Neyra J, Jacobsen G, Novak JE, Are Women at Higher Risk to Develop Radiocontrast-induced nephropathy (RCIN) following coronary angiography?, Presented at: National Kidney Foundation 2011, Washington, DC, 26–30 April, 2011.
40. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, 2010. Available at: www.usrds.org/adr.htm
(accessed 26 June 2011).
41. Gruberg L, Mintz GS, Mehran R, et al., The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency, J Am Coll Cardiol, 2000;36(5):1542–8.
42. Prins JM, Buller HR, Kuijper EJ, et al., Once versus thrice daily gentamicin in patients with serious infections, Lancet, 1993;341(8841):335–9.
43. Freeman RV, O'Donnell M, Share D, et al., Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose, Am J Cardiol, 2002;90(10):1068–73.
44. Maioli M, Toso A, Gallopin M, et al., Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention, J Cardiovasc Med (Hagerstown), 2010;11(6):444–9.
45. Madsen TE, Pearson RR, Muhlestein JB, et al., Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography, Crit Pathw Cardiol, 2009;8(4):167–71.
46. Stolker JM, McCullough PA, Rao S, et al., Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography, J Am Coll Cardiol, 2010;55(14):1433–40.
47. Kosiborod M, Rathore SS, Inzucchi SE, et al., Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes, Circulation, 2005;111(23):3078–86.
48. Kosiborod M, Inzucchi SE, Krumholz HM, et al., Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk, Circulation, 2008;117(8):1018–27.
49. Gleeson TG, Bulugahapitiya S, Contrast-Induced Nephropathy, Am J Roentgenol, 2004;183(6):1673–89.
50. Marenzi G, Lauri G, Assanelli E, et al., Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction, J Am Coll Cardiol, 2004;44(9):1780–5.
51. Dangas G, Iakovou I, Nikolsky E, et al., Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables, Am J Cardiol, 2005;95(1):13–9.
52. Cigarroa RG, Lange RA, Williams RH, Hillis LD, Dosing of contrast material to prevent contrast nephropathy in patients with renal disease, Am J Med, 1989;86(6 Pt 1):649–52.
53. Marenzi G, Assanelli E, Campodonico J, et al., Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality, Ann Intern Med, 2009;150(3):170–7.
54. Brown JR, Robb JF, Block CA, et al., Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?, Circ Cardiovasc Interv, 2010;3(4):346–50.
55. Solomon R, Nephrotoxicity of iodixanol versus iopamidol inpatients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures, Am Heart J, 2010;159(2):e7; author reply e9.
56. Hernandez F, Mora L, Garcia-Tejada J, et al., Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty, Rev Esp Cardiol, 2009;62(12):1373–80.
57. Reed M, Meier P, Tamhane UU, et al., The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials, JACC Cardiovasc Interv, 2009;2(7):645–54.
58. Wessely R, Koppara T, Bradaric C, et al., Choice of contrast medium in patients with impaired renal function undergoing
percutaneous coronary intervention, Circ Cardiovasc Interv, 2009;2(5):430–7.
59. Pannu N, Wiebe N, Tonelli M, Alberta Kidney Disease N. Prophylaxis strategies for contrast-induced nephropathy, JAMA, 2006;295(23):2765–79.
60. Zoungas S, Ninomiya T, Huxley R, et al., Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy, Ann Intern Med, 2009;151(9):631–8.
61. Meier P, Ko DT, Tamura A, et al., Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis, BMC Med, 2009;7:23.
62. Kanbay M, Covic A, Coca SG, et al., Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials, Int Urol Nephrol, 2009;41(3):617–27.
63. Calabro P, Bianchi R, Caprile M, et al., Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography, Minerva Cardioangiol, 2010;58(1):35–40.
64. Hou SH, Bushinsky DA, Wish JB, et al., Hospital-acquired renal insufficiency: a prospective study, Am J Med, 1983;74(2):243–8.
65. Hatala R, Dinh TT, Cook DJ, Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review, Clin Infect Dis, 1997;24(5):810–5.
66. Hock R, Anderson RJ, Prevention of drug-induced nephrotoxicity in the intensive care unit, J Crit Care, 1995;10(1):33–43.
67. Taber SS, Mueller BA, Drug-Associated Renal Dysfunction, Critical Care Clinics, 2006;22(2):357.
68. Tran DD, Oe PL, de Fijter CW, van der Meulen J, Cuesta MA. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome, Nephrol Dial Transplant, 1993;8(10):1079–84.
69. Walsh TJ, Hiemenz JW, Seibel NL, et al., Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis, 1998;26(6):1383–96.
70. Whelton A, Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications, Am J Med, 1999;106(5B):13S–24S.
71. Perazella MA, Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity, Am J Med Sci, 2003;325(6):349–62.
72. Louis BM, Hoch BS, Hernandez C, et al., Protection from the nephrotoxicity of contrast dye, Ren Fail, 1996;18(4):639–46.
73. Kiski D, Stepper W, Brand E, et al., Impact of renin- angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial, Nephrol Dial Transplant, 2010;25(3):759–64.
74. Gupta RK, Kapoor A, Tewari S, et al., Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study, Indian Heart J, 1999;51(5):521–6.
75. Yoshioka T, Fogo A, Beckman JK, Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion, Kidney Int, 1992;41(4):1008–15.
76. Parvez Z, Rahman MA, Moncada R, Contrast media-induced lipid peroxidation in the rat kidney, Invest Radiol, 1989;24(9):697–702.
77. Tepel M, van der Giet M, Schwarzfeld C, et al., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine, N Engl J Med, 2000;343(3):180–4.
78. Nallamothu BK, Shojania KG, Saint S, et al., Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis, Am J Med, 2004;117(12):938–47.
79. Kelly AM, Dwamena B, Cronin P, et al., Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy, Ann Intern Med, 2008;148(4):284–94.
80. Trivedi H, Daram S, Szabo A, et al., High-dose N- acetylcysteine for the prevention of contrast-induced nephropathy, Am J Med, 2009;122(9):874.
81. Conen D, Buerkle G, Perruchoud AP, et al., Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention, Int J Cardiol, 2006;110(2):237–41.
82. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al., The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study, J Am Coll Cardiol, 2003;42(2):211–6.
83. Brown JR, Kramer RS, Coca SG, Parikh CR, Duration of acute kidney injury impacts long-term survival after cardiac surgery, Ann Thorac Surg, 2010;90(4):1142–8.
84. Solomon RJ, Mehran R, Natarajan MK, et al., Contrast- induced nephropathy and long-term adverse events: cause and effect?, Clin J Am Soc Nephrol, 2009;4(7):1162–9.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92